Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal clinical study for feline chronic gingivostomatitis (FCGS) and advancement of next-generation Ainos Flora with Nvidia CUDA implementation.</li><li>Financials. 2Q24 revenue was $0, as Ainos has pivoted away from COVID-19 antigen tests and focuses on AI Nose for the POCT platform and Veldona drugs.</li><li>Pet supplement product revenue in the quarter was deferred in contract liabilities. </li></ul>

Ainos reported 2Q24 earnings, highlighting the pipeline progress in the quarter, including enrollment of the first subject in the Veldona animal clinical study for feline chronic gingivostomatitis (FCGS) and advancement of next-generation Ainos Flora with Nvidia CUDA implementation.Financials. 2Q24 revenue was $0, as Ainos has pivoted away from COVID-19 antigen tests and focuses on AI Nose for the POCT platform and Veldona drugs.Pet supplement product revenue in the quarter was deferred in contract liabilities. 

Ainos

Ainos, Inc. - Earnings Update